Novel B cell targetting therapies in systemic autoimmune diseases
| Project/Area Number |
26461466
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Collagenous pathology/Allergology
|
|---|
| Research Institution | Saga University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
TASHIRO Satoko
NAGAO Natsumi
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | plasmablast / B細胞 / CD180(RP105) / 自己免疫疾患 / IgG4関連疾患 / SLE / 自己抗体 / 抗体免疫療法 / 治療 / Ｂ細胞 |
|---|
| Outline of Final Research Achievements |
CD180 (RP105) molecule is expressed on B cells. RP105 is associated with B cell function, survival and death. RP105-lacking B cells produce autoantibodies, including anti-ds-DNA antibodies in SLE. Large population of plasmablasts lacking RP105 are found in patients with systemic autoimmune diseases and take part in pathophysiology. We have studied clinical significance of RP105-negative B cells including plasmablasts in various immune-based diseases. We also analyzed the 5 sub-populations of plasmablasts in the various diseases. RP105-negative plasmablasts play crucial roles in systemic autoimmune and immune-based inflammatory disorders. Also, distribution of sub-population and difference of expressed antigens in RP105-lacking plasmablasts may be associated with pathophysiology in individual disorders.
|
Report
(4 results)
Research Products
(24 results)
-
[Journal Article] The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis.2016
Author(s)
Tada Y, Ono N, Suematsu R, Tashiro S, Sadanaga Y, Tokuda Y, Ono Y, Nakao Y, Maruyama A, Ohta A, Koarada S.
-
Journal Title
BMC Musculoskelet Disord
Volume: 17
Issue: 1
Pages: 1-7
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
[Journal Article] Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors.2015
Author(s)
Koarada S, Tsuboi M, Komine M, Nakao Y, Tokuda Y, Ono Y, Tashiro S, Maruyama A, Ono N, Ohta A, Tada Y.
-
Journal Title
Case Rep Rheumatol.
Volume: 2015
Pages: 348614-348614
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
